Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia.
Immunotherapy (eg interferon α) in combination with tyrosine kinase inhibitors is currently in clinical trials for treatment of chronic myeloid leukemia (CML). Cancer patients commonly have problems with so called immune escape mechanisms that may hamper immunotherapy. Hence, to study the function o...
Guardado en:
Autores principales: | Lisa Christiansson, Stina Söderlund, Emma Svensson, Satu Mustjoki, Mats Bengtsson, Bengt Simonsson, Ulla Olsson-Strömberg, Angelica S I Loskog |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/99ac963924154cd7b2914f98023d20ec |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Engagement of SIRPα inhibits growth and induces programmed cell death in acute myeloid leukemia cells.
por: Mahban Irandoust, et al.
Publicado: (2013) -
Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Wei-Bo Yu, et al.
Publicado: (2019) -
Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
por: Otgontuya Ganbaatar, et al.
Publicado: (2021) -
Flow Cytometric Measurement of Blood Cells with BCR-ABL1 Fusion Protein in Chronic Myeloid Leukemia
por: Liza Löf, et al.
Publicado: (2017) -
STRATEGY OF PROGRAMMED CELL DEATH IN PROKARYOTES
por: B. G. Andrukov, et al.
Publicado: (2015)